Free Trial

Profound Medical Q4 2024 Earnings Report

Profound Medical logo
$6.50 -0.18 (-2.69%)
As of 03/26/2025 03:59 PM Eastern

Profound Medical EPS Results

Actual EPS
-$0.20
Consensus EPS
-$0.31
Beat/Miss
Beat by +$0.11
One Year Ago EPS
N/A

Profound Medical Revenue Results

Actual Revenue
$4.18 million
Expected Revenue
$5.92 million
Beat/Miss
Missed by -$1.74 million
YoY Revenue Growth
N/A

Profound Medical Announcement Details

Quarter
Q4 2024
Time
After Market Closes
Remove Ads

Profound Medical Earnings Headlines

Trump’s betrayal exposed
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.
See More Profound Medical Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Profound Medical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Profound Medical and other key companies, straight to your email.

About Profound Medical

Profound Medical (NASDAQ:PROF), together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum. The company also offers Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. Profound Medical Corp. is headquartered in Mississauga, Canada.

View Profound Medical Profile

More Earnings Resources from MarketBeat